Financial Data and Key Metrics Changes - The company ended 2025 with approximately $292.3 million in cash and marketable securities, remaining debt-free with about 31.3 million shares outstanding [32][33] - Q4 2025 net product revenues were approximately $1.6 million, with over 20,000 monthly paid and filled prescriptions [33] - Total Q4 operating expenses were approximately $40 million, with a net cash burn of about $32 million [34][35] - The net loss per share in Q4 2025 was $1.16, compared to a net loss per share of $0.46 in Q4 2024 [37] Business Line Data and Key Metrics Changes - The company sold over 45,000 boxes of LNZ100, prescribed by more than 10,000 eye care professionals, indicating strong adoption [7][26] - The product is showing encouraging refill behavior, with patients moving from one-month to three-month prescriptions [48][76] Market Data and Key Metrics Changes - Presbyopia affects approximately 128 million people in the United States, representing a significant market opportunity for the company [6][18] - The company is seeing a broad base of prescribing physicians, with over 55% of ECPs having written VIZZ multiple times [21][22] Company Strategy and Development Direction - The company aims to build a new treatment category for presbyopia, focusing on accelerating adoption through enhanced physician messaging and expanding the sales force [12][19] - The direct-to-consumer campaign launched in January is expected to take at least two quarters to translate into prescription trends, with early indicators showing positive engagement [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the product's effectiveness and the encouraging early signals of patient persistence, indicating a strong foundation for future growth [16][42] - The company is focused on executing its strategy to build a blockbuster category, leveraging both physician and consumer adoption [16][42] Other Important Information - The company plans to maintain a significant portion of its operating expenses towards sales and marketing, targeting approximately 75%-80% [39] - The company is advancing its global expansion strategy, with potential approvals in multiple geographies anticipated in early 2027 [40][41] Q&A Session Questions and Answers Question: Can you discuss the sampling dynamic to NRX and retention? - Management feels good about the NRX and refill dynamic, noting that patients who purchase continue to use the product, with encouraging refill rates observed [46][48] Question: What investments are being made to broaden patient demand? - The focus is on digital advertising and optimizing media placements to effectively reach target demographics, with a selective approach to linear TV advertising in key markets [50][51] Question: What percentage of prescribers are from the initial target group versus inbounds from patient demand? - The company has expanded its target group from 12,000 to 15,000 ECPs, with many new prescribers being those who had never written Vuity before [53][54] Question: Can you provide insights on the behavior of the top 1,000 prescribers? - The top prescribers are more comfortable with new technologies and have successfully integrated VIZZ into their patient discussions, setting appropriate expectations for its use [59][63]

Financial Data and Key Metrics Changes - The company ended Q4 2025 with approximately $292.3 million in cash and marketable securities, remaining debt-free with about 31.3 million shares outstanding [32] - Q4 net product revenues were approximately $1.6 million, with over 20,000 monthly paid and filled prescriptions [32] - Operating expenses for Q4 totaled approximately $40 million, with a net cash burn of about $32 million [33][34] - The net loss per share for Q4 was $1.16, compared to a net loss per share of $0.46 in Q4 2024 [35] Business Line Data and Key Metrics Changes - The launch of LNZ100 has resulted in over 45,000 boxes sold, prescribed by more than 10,000 eye care professionals [5][26] - The product is showing strong refill behavior, with patients moving from one-month to three-month prescriptions [48][72] Market Data and Key Metrics Changes - Presbyopia affects approximately 128 million people in the U.S., representing a significant market opportunity [18] - The company is seeing a broad base of prescribing physicians, with over 55% of doctors having written VIZZ multiple times [20] Company Strategy and Development Direction - The company aims to build a new treatment category for presbyopia, focusing on increasing physician adoption and consumer awareness [16][19] - The sales force is expanding from 88 to 117 representatives to increase call frequency and broaden coverage of eye care professionals [24][25] - A direct-to-consumer campaign featuring Sarah Jessica Parker has been launched to drive consumer engagement [27][28] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the product's performance and the potential for a large, under-penetrated market [16][30] - The company expects to see an acceleration in new patient starts as prescriber habits build and consumer awareness grows [41] Other Important Information - The company has made significant progress in global expansion, with multiple NDA submissions anticipated in early 2027 [39][40] - The direct-to-consumer campaign is showing early positive indicators, with website traffic increasing significantly [13][28] Q&A Session Summary Question: Can you discuss the sampling dynamic to NRX and retention? - Management is encouraged by refill rates and believes the sampling strategy is effective, with patients returning for reorders [46][48] Question: What investments are being made to broaden patient demand? - The focus is on digital advertising and optimizing media placements to effectively reach target demographics [50][51] Question: What percentage of prescribers are from the initial target group versus inbounds from patient demand? - The company is seeing growth in prescribers from both targeted and non-targeted groups, with many new prescribers who had not previously written Vuity now adopting VIZZ [52][53] Question: Can you elaborate on the behavior of the top prescribers? - The top prescribers are effectively integrating VIZZ into their practices and are comfortable offering it to a broader patient population [59][63] Question: How are you planning to correct misconceptions about VIZZ's target population? - The company is actively working to educate prescribers on the broader applicability of VIZZ beyond early presbyopes [64]

Core Viewpoint - LENZ Therapeutics has successfully launched VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia treatment, generating $1.6 million in net product revenues in the first quarter post-launch, with strong prescriber adoption and positive early refill trends [1][9]. Commercial Launch - VIZZ was first commercially sold in October 2025, with Q4 2025 product revenue of approximately $1.6 million from over 20,000 filled prescriptions [6]. - The company is on track for over 45,000 paid prescriptions from launch through Q1 2026, with over 6,500 unique prescribers in Q4 2025, expected to grow to over 10,000 by Q1 2026 [6][9]. Prescriber Adoption and Marketing Strategy - The early performance of VIZZ is encouraging, with broad prescriber uptake and positive refill dynamics, indicating its best-in-class profile [2]. - The company is expanding its sales force from 88 to 117 territories to enhance engagement with eye care professionals (ECPs) and is implementing targeted consumer campaigns to position VIZZ as a viable alternative to reading glasses [5][2]. Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $292.3 million, which is expected to support operations until achieving positive operating cash flow post-launch [9]. - The net loss for Q4 2025 was $35.9 million, or $1.16 per share, compared to a net loss of $12.7 million, or $0.46 per share, in Q4 2024 [14][28]. International Expansion and Partnerships - LENZ submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ and has established multiple international partnerships, including an exclusive commercialization agreement with Lunatus for the Middle East [15][24]. - The company has also made regulatory submissions in Thailand, Singapore, South Korea, and China for VIZZ [15]. Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [18][19]. - The product is preservative-free and provided in single-dose vials, targeting the treatment of presbyopia, a condition affecting approximately 1.8 billion people globally [24].

Core Insights - LENZ Therapeutics, Inc. is focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved eye drop for treating presbyopia in adults [1][3] - The company will host a webcast on March 24, 2026, to report its fourth quarter and full year 2025 financial results and recent corporate highlights [1] Company Overview - LENZ Therapeutics is headquartered in San Diego, California, and is commercializing VIZZ in the United States while establishing international licensing partnerships [3] - Presbyopia affects an estimated 1.8 billion people globally, including 128 million in the United States [3]

Core Viewpoint - Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics by 48.9% during the third quarter, indicating a potential shift in investment strategy or confidence in the company [2] Institutional Investment Activity - Versant Venture Management LLC acquired a new stake in LENZ Therapeutics valued at approximately $123.76 million during the third quarter [3] - Adage Capital Partners GP L.L.C. increased its stake by 108.8% in the second quarter, now holding 1,122,738 shares worth $32.91 million after acquiring an additional 585,000 shares [3] - Franklin Resources Inc. raised its position by 6,756.1% in the third quarter, owning 587,084 shares valued at $27.35 million after acquiring 578,521 shares [3] - UBS Group AG increased its stake by 36.3% in the third quarter, now owning 1,201,616 shares valued at $55.97 million after acquiring 320,135 shares [3] - Hedge funds and institutional investors collectively own 54.32% of LENZ Therapeutics [3] Analyst Ratings - HC Wainwright maintained a "buy" rating for LENZ Therapeutics [4] - Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Zacks Research downgraded the stock from "strong-buy" to "hold" [4] - Weiss Ratings reiterated a "sell (d-)" rating [4] - William Blair reissued an "outperform" rating [4] - The consensus rating for LENZ Therapeutics is "Moderate Buy" with a price target of $56.40 [4] Stock Performance - LENZ Therapeutics opened at $12.15, with a market cap of $380.17 million [5] - The stock has a 50-day simple moving average of $15.01 and a 200-day simple moving average of $25.99 [5] - The one-year low for the stock is $11.21, while the one-year high is $50.40 [5] - The company has a P/E ratio of -5.76 and a beta of 0.52 [5] Company Overview - LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies to improve vision in the U.S. [6] - Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for treating presbyopia [6]

Summary of LENZ Therapeutics Conference Call Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Product**: Eye drop for treating presbyopia, named VIZZ - **Launch Timeline**: Product approved in August and launched in October 2025 Industry Context - **Market Size**: Approximately 120 million presbyopes in the U.S. [18] - **Competitive Landscape**: - LENZ is the only company with aceclidine as an active ingredient - Competitors include AbbVie's VUITY (pilocarpine-based) and Qlosi (low-dose pilocarpine), both of which have shown limited efficacy [12][13] - VUITY had a 25% effectiveness rate, with only 1 in 4 patients noticing an effect [12] - VUITY's sales force has significantly reduced, indicating market struggles [13] Product Efficacy - **Mechanism of Action**: Aceclidine stimulates the iris sphincter to create a smaller pupil, enhancing near vision without affecting distance vision [9][10] - **Clinical Trial Results**: - 71% of patients experienced significant near vision improvement after 10 hours of use [8] - The product is designed to provide near vision improvement for the majority of the day [8] Launch Insights - **Initial Feedback**: Positive reception from both doctors and patients, with high awareness and willingness to prescribe [30][31] - **Refill Rates**: Early indications show encouraging refill rates, suggesting product stickiness [29] - **Sampling Strategy**: A robust sampling strategy is in place, allowing patients to try the product before committing to a prescription [29][40] Sales and Marketing Strategy - **Sales Force Expansion**: Plans to increase the sales force to 117 representatives to enhance market penetration [34] - **Target Audience**: 80% of prescriptions are written by optometrists, with the remaining 20% by ophthalmologists [46] - **Geographic Focus**: Strong sales in states like Florida, California, New York, and Texas [49] Safety and Side Effects - **Adverse Events**: Minimal reports of side effects such as headaches, redness, or dimness, with most effects being short-lived [85][90] - **Retinal Issues**: LENZ has reported only one case of retinal tear, compared to 34 reported by VUITY, indicating a safer profile [91][96] Market Expectations - **Sales Projections**: Consensus estimates for quarterly sales are around $2 million, with annual projections between $35-$40 million [129][130] - **Investor Sentiment**: There is impatience in the investment community regarding script data, but the company emphasizes the importance of building a market and establishing a solid foundation [168][170] Future Plans - **Direct-to-Consumer Campaign**: A DTC campaign has been initiated to increase awareness and drive prescriptions, with early signs of increased web traffic and interest [146][148] - **International Expansion**: The company is pursuing partnerships for international commercialization, with recent filings in Europe [173] Conclusion - LENZ Therapeutics is positioned uniquely in the presbyopia market with a product that shows promising efficacy and safety. The company is focused on expanding its market presence through strategic sales efforts and marketing campaigns while addressing investor concerns about growth and market penetration.

Core Viewpoint - LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ, an aceclidine ophthalmic solution, marking a significant step in expanding global access to this treatment for presbyopia [1][3] Group 1: Regulatory Submission and Milestones - The MAA submission to the EMA represents the fifth regulatory submission for VIZZ outside the U.S. [1] - If approved, VIZZ will be available to millions of Europeans suffering from age-related blurry near vision [1][3] - The submission is part of LENZ's strategy to establish VIZZ as a global brand, with ongoing commercialization efforts in various regions including Greater China, South Korea, and the Middle East [3] Group 2: Clinical Data and Efficacy - The MAA is supported by positive results from three Phase 3 CLARITY trials conducted in the U.S., where VIZZ met all primary and secondary endpoints, improving near vision within 30 minutes and lasting up to 10 hours [2] - VIZZ was well tolerated, with no serious treatment-related adverse events reported over 30,000 treatment days across the trials [2] Group 3: Market Opportunity and Company Strategy - Presbyopia affects approximately 1.8 billion people globally, with Europe being a significant market for vision correction products [3] - The company aims to pursue commercialization in Europe through strategic partnerships, complementing existing partnerships in other regions [3][4]

LENZ Therapeutics FY Conference Summary Company Overview - **Company**: LENZ Therapeutics (NasdaqGS:LENZ) - **Product**: VIZZ, a presbyopia eye drop launched in October 2025 Key Points Product Launch and Market Reception - VIZZ is a once-a-day eye drop that can replace reading glasses, providing up to 10 hours of near vision improvement [2][11] - The product has received positive feedback from both doctors and patients, with anecdotal reports of efficacy lasting up to 12 hours [11] - The company has distributed samples to approximately 15,000 target doctors, encouraging patient trials [4] Clinical and Real-World Efficacy - Clinical studies showed strong results, and real-world experiences confirm that the product works effectively [3] - Patients are reportedly moving from single packs to multi-packs, indicating satisfaction and stickiness with the product [5] Doctor Engagement and Sales Strategy - The number of prescribing doctors has grown from 6,500 in January to a rapidly increasing number, with a focus on making VIZZ a regular part of patient discussions [6] - The sales force is being expanded to meet demand from doctors outside the initial target group [7][34] Direct-to-Consumer (DTC) Campaign - A DTC campaign launched in January 2026 features spokesperson Sarah Jessica Parker, aiming to increase patient awareness and demand [27][30] - Early indicators show a significant increase in website visits and patient inquiries, although it may take time to translate into prescriptions [28][57] Market Potential - The presbyopia market is estimated to have 128 million potential patients, with a projected $3 billion market size at a 6% penetration rate [42] - The company is focused on converting trial users into regular customers, with encouraging refill rates observed [43][44] Side Effects and Safety - Mild and transient side effects, such as hyperemia (eye redness), have been reported but are generally short-lived [14][15] - Concerns regarding retinal detachments have been addressed, with the company reporting only one case linked to a patient with a history of retinal issues [18][19] Competitive Landscape - The company believes that the market can support multiple effective products, emphasizing the unique efficacy of VIZZ compared to competitors [61][62] - The management is confident in the product's performance and its ability to capture market share [63] Investor Insights - The company is focused on execution and driving script growth, with a healthy cash balance allowing for continued investment in sales and marketing [65] - Management believes that the share price will reflect the company's performance as it successfully connects product efficacy with market demand [65] Demographics and Usage Trends - The user demographic skews 60% female and 40% male, primarily aged 45-65, but the product is effective across a broader range [48] - The pricing strategy includes a retail price of $79 per pack, with a net price of approximately $60 after discounts [49] Conclusion - LENZ Therapeutics is in the early stages of launching VIZZ, with positive initial feedback and a strong market potential. The company is actively expanding its sales force and DTC efforts to drive adoption and ensure long-term success in the presbyopia market [66]

Core Viewpoint - The FDA has accepted Viatris' supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) aimed at treating presbyopia, with a PDUFA goal date set for October 17, 2026, indicating progress in the company's innovative pipeline [1][2]. Group 1: Product Development - MR-141 is designed to treat presbyopia, a condition affecting approximately 90% of adults over 45 in the U.S., leading to blurred near vision and eye strain [1]. - The sNDA is supported by data from pivotal Phase 3 trials, VEGA-2 and VEGA-3, which met primary and key secondary endpoints without serious adverse events [1][2]. - Data from the VEGA-3 trial will be presented at upcoming ophthalmology meetings, highlighting the product's efficacy [1]. Group 2: Market Context - Presbyopia affects nearly 128 million people in the U.S., with a global estimate of 1.8 billion people affected in 2015, projected to rise to 2.1 billion by 2030 [1]. - Ryzumvi® is currently the only FDA-approved product for treating pharmacologically-induced mydriasis, and the sNDA seeks to expand its indication to include presbyopia [1][2]. Group 3: Company Overview - Viatris is positioned to bridge the gap between generics and brands, providing access to high-quality medicines for approximately 1 billion patients annually [1]. - The company operates globally with headquarters in the U.S. and centers in Pittsburgh, Shanghai, and Hyderabad, India [1].

Core Insights - The FDA has approved Tenpoint Therapeutics Ltd.'s Yuvezzi, the first dual-agent eye drop for presbyopia, which affects approximately two billion people globally and 128 million in the U.S. [1] Group 1: Product Approvals and Market Impact - Yuvezzi is expected to be commercially available in the U.S. by Q2 2026, while LENZ Therapeutics' VIZZ was approved in August 2025 as the first aceclidine-based eye drop for presbyopia [2] - Following the approval of Yuvezzi, LENZ Therapeutics' stock fell around 9% [2] Group 2: Analyst Perspectives - Analysts from William Blair believe the stock drop for LENZ is an overreaction, asserting that VIZZ maintains a best-in-class profile despite the new competition from Yuvezzi [3] - VIZZ is noted for its greater efficacy, faster onset, and longer durability compared to Yuvezzi, which introduces new risks not present in the VIZZ label [4] - The differences in product labels may not significantly influence eye care professionals' perceptions or real-world uptake, but they provide LENZ's commercial team with additional talking points [5] Group 3: Commercial Strategy and Performance - LENZ is focused on executing the launch of VIZZ, having made progress in raising awareness and prescribing among eye care professionals, and is set to launch a direct-to-consumer campaign [6] - Analysts continue to believe VIZZ has blockbuster potential and maintain an Outperform rating on LENZ shares [6] Group 4: Stock Performance - LENZ Therapeutics shares were down 8.89% at $16.20, nearing a 52-week low of $14.43 [7]